IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, N43DA-13-7

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43DA130037
Agency Tracking Number: N43DA130037
Amount: $338,884.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NIDA
Solicitation Number: N/A
Small Business Information
522 Second Avenue, REDWOOD CITY, CA, 94063-3848
DUNS: 160127655
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (650) 784-5658
Business Contact
Phone: (650) 784-5658
Research Institution
Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profilefour FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated inObjective 1. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government